65 related articles for article (PubMed ID: 1777064)
21. Remacemide.
Muir KT; Palmer GC
Epilepsy Res Suppl; 1991; 3():147-52. PubMed ID: 1777071
[No Abstract] [Full Text] [Related]
22. Tiagabine.
Pierce MW; Suzdak PD; Gustavson LE; Mengel HB; McKelvy JF; Mant T
Epilepsy Res Suppl; 1991; 3():157-60. PubMed ID: 1777074
[No Abstract] [Full Text] [Related]
23. Oxcarbazepine.
Jensen PK; Gram L; Schmutz M
Epilepsy Res Suppl; 1991; 3():135-40. PubMed ID: 1777069
[No Abstract] [Full Text] [Related]
24. [New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
Herranz JL; Arteaga R; Armijo JA
Neurologia; 1994 Nov; 9(9):410-7. PubMed ID: 7811493
[No Abstract] [Full Text] [Related]
25. Vigabatrin.
Mumford JP; Lewis PJ
Epilepsy Res Suppl; 1991; 3():161-8. PubMed ID: 1777075
[No Abstract] [Full Text] [Related]
26. Stiripentol.
Vincent JC
Epilepsy Res Suppl; 1991; 3():153-6. PubMed ID: 1777073
[No Abstract] [Full Text] [Related]
27. Zonisamide.
Seino M; Miyazaki H; Ito T
Epilepsy Res Suppl; 1991; 3():169-74. PubMed ID: 1777076
[No Abstract] [Full Text] [Related]
28. Ralitoline.
Anhut H; Satzinger G; von Hodenberg A
Epilepsy Res Suppl; 1991; 3():141-5. PubMed ID: 1777070
[No Abstract] [Full Text] [Related]
29. Lamotrigine.
Yuen AW
Epilepsy Res Suppl; 1991; 3():115-23. PubMed ID: 1777066
[No Abstract] [Full Text] [Related]
30. Gabapentin.
Foot M; Wallace J
Epilepsy Res Suppl; 1991; 3():109-14. PubMed ID: 1777065
[No Abstract] [Full Text] [Related]
31. Felbamate.
Bourgeois BF
Semin Pediatr Neurol; 1997 Mar; 4(1):3-8. PubMed ID: 9097361
[TBL] [Abstract][Full Text] [Related]
32. Felbamate.
Leppik IE
Epilepsia; 1995; 36 Suppl 2():S66-72. PubMed ID: 8784215
[TBL] [Abstract][Full Text] [Related]
33. Antiepileptic drugs in clinical development.
Ramsay RE; Slater JD
Epilepsy Res Suppl; 1993; 10():45-67. PubMed ID: 8251106
[No Abstract] [Full Text] [Related]
34. Felbamate: clinical and molecular aspects of a unique antiepileptic drug.
Brown WM; Aiken SP
Crit Rev Neurobiol; 1998; 12(3):205-22. PubMed ID: 9847055
[TBL] [Abstract][Full Text] [Related]
35. Is there any future for felbamate treatment?
Borowicz KK; Piskorska B; Kimber-Trojnar Z; Małek R; Sobieszek G; Czuczwar SJ
Pol J Pharmacol; 2004; 56(3):289-94. PubMed ID: 15215558
[TBL] [Abstract][Full Text] [Related]
36. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy.
Palmer KJ; McTavish D
Drugs; 1993 Jun; 45(6):1041-1065. PubMed ID: 7691493
[TBL] [Abstract][Full Text] [Related]
37. Felbamate in epilepsy therapy: evaluating the risks.
Pellock JM
Drug Saf; 1999 Sep; 21(3):225-39. PubMed ID: 10487399
[TBL] [Abstract][Full Text] [Related]
38. Felbamate pharmacology and use in epilepsy.
Burdette DE; Sackellares JC
Clin Neuropharmacol; 1994 Oct; 17(5):389-402. PubMed ID: 9316688
[TBL] [Abstract][Full Text] [Related]
39. Felbamate: successful development of a new compound for the treatment of epilepsy.
Schmidt D
Epilepsia; 1993; 34 Suppl 7():S30-3. PubMed ID: 8243376
[TBL] [Abstract][Full Text] [Related]
40. Investigational antiepileptic drugs for the treatment of childhood seizure disorders: a review of efficacy and safety.
Shields WD
Epilepsia; 1994; 35 Suppl 2():S24-9. PubMed ID: 8275978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
